Table 1 Clinical characteristics by group.
Measurement | Other (Control) | DH/TH | p | Alt-DH/TH | p |
|---|---|---|---|---|---|
N | 407 (85.0%) | 21 (4.4%) | 51 (10.6%) | ||
Age | 0.56 | 0.36 | |||
 >60 | 286 (70.3%) | 16 (76.2%) | 39 (76.4%) | ||
 ≦60 | 121 (29.7%) | 5 (23.2%) | 12 (23.6%) | ||
Sex | 0.14 | 0.96 | |||
 Male | 230 (56.5%) | 11 (52.4%) | 29 (56.9%) | ||
 Female | 177 (43.5%) | 10 (47.6%) | 22 (43.1%) | ||
IPI | 0.50 | 0.31 | |||
 0–1 | 160 (39.3%) | 5 (23.8%) | 19 (37.3%) | ||
 2 | 99 (24.3%) | 6 (28.6%) | 10 (19.6%) | ||
 3 | 97 (23.8%) | 6 (28.6%) | 18 (35.3%) | ||
 4–5 | 49 (12.0%) | 4 (19.0%) | 4 (7.8%) | ||
NA = 2 | |||||
Stage | 0.13 | 0.96 | |||
 I–II | 185 (45.5%) | 6 (28.6%) | 23 (45.1%) | ||
 III–IV | 222 (54.5%) | 15 (71.4%) | 28 (54.9%) | ||
COO | 0.01 | 0.24 | |||
 ABC-like | 151 (37.1%) | 3 (14.2%) | 15 (29.4%) | ||
 GCB | 160 (39.3%) | 16 (76.2%) | 27 (52.9%) | ||
 Unclassified | 36 (8.8%) | 1 (4.8%) | 2 (3.9%) | ||
 NA | 60 (14.7%) | 1 (4.8%) | 7 (13.8%) | ||
Cohort | 0.27 | 0.31 | |||
 Mayo | 222 (54.6%) | 14 (66.7%) | 24 (47.1%) | ||
 Chapuy et al. | 185 (45.4%) | 7 (33.3%) | 27 (52.9%) |
